Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Harvard Bioscience ( (HBIO) ) is now available.
On July 17, 2025, Harvard Bioscience announced a CEO succession plan with John Duke set to replace Jim Green as President & CEO, effective July 28, 2025. Jim Green is retiring after more than eight years as Chairman and six years as President & CEO. Additionally, Rob Gagnon and Seth Benson were appointed as new independent directors to the Board. The company also anticipates second quarter 2025 revenue to be $20.4 million and reiterated its gross margin guidance for the same period. These leadership changes and financial expectations are poised to impact Harvard Bioscience’s operations and strategic direction, potentially enhancing its market position and value creation for shareholders.
The most recent analyst rating on (HBIO) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Harvard Bioscience stock, see the HBIO Stock Forecast page.
Spark’s Take on HBIO Stock
According to Spark, TipRanks’ AI Analyst, HBIO is a Neutral.
Harvard Bioscience scores low due to significant financial challenges and poor valuation metrics. Technical indicators suggest bearish momentum, further impacting the score. The earnings call offers some optimism with product launches and cash flow improvements, but substantial operational challenges remain, particularly revenue decline and market difficulties.
To see Spark’s full report on HBIO stock, click here.
More about Harvard Bioscience
Harvard Bioscience, Inc. is a leading developer, manufacturer, and seller of technologies, products, and services that enable fundamental advances in life science applications. These include research, drug and therapy discovery, bio-production, and preclinical testing for pharmaceutical and therapy development. The company serves a diverse customer base, including academic institutions, government laboratories, and leading pharmaceutical, biotechnology, and contract research organizations, with operations in the United States, Europe, and China.
Average Trading Volume: 12,533,958
Technical Sentiment Signal: Sell
Current Market Cap: $17.64M
For detailed information about HBIO stock, go to TipRanks’ Stock Analysis page.